Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.86 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | XIAP | P98170 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL10804023 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL20703797 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL4629448 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL9937710 | 1.00 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL2284689 | 0.95 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL28049225 | 0.95 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL28019917 | 0.95 | SLC7A5 (0.77) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL1853798 | 0.94 | SLC7A5 (0.75) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL29780694 | 0.93 | SLC7A5 (0.86) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL6374042 | 0.93 | SLC7A5 (0.92) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137907-A2 | METHODS FOR IDENTIFYING T CELL RECEPTORS (TCRS) THAT BIND ANTIGENS | BLUESPHERE BIO, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20230192765-A1 | PEPTIDES TARGETING SHP2 AND USES THEREOF | Università Degli Studi di Roma "Tor Vergata" (IT) | 2023-06-22 | — | — | US | disclosed |
| US-20230137491-A1 | PEPTIDES AND USES THEREOF | Sintica Biotech Società A Responsabilità Limitata Semplificata (IT) | 2023-05-04 | — | — | US | disclosed |
| US-20230055953-A1 | AGENT FOR ADJUVANT THERAPY | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-4132957-A1 | PEPTIDES AND USES THEREOF | Sintica Biotech Societa a Responsabilita Limitata Semplificata (IT) | 2023-02-15 | — | — | EP | disclosed |
| EP-4114849-A1 | PEPTIDES TARGETING SHP2 AND USES THEREOF | Universita' degli Studi di Roma " Tor Vergata" (IT) | 2023-01-11 | — | — | EP | disclosed |
| WO-2021205001-A9 | PEPTIDES AND USES THEREOF | MARCONI ALESSANDRA (IT) | 2022-01-13 | — | — | WO | disclosed |
| US-20210401745-A1 | EMULSION FORMULATION AND METHOD FOR PREPARING THE SAME | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
| US-11179471-B2 | Peptide for cytosolic delivery | KYOTO UNIVERSITY (JP) | 2021-11-23 | — | — | US | disclosed |
| EP-3878463-A1 | EMULSION PREPARATION AND PREPARATION METHOD THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2021-09-15 | — | — | EP | disclosed |
| EP-3061771-A1 | NOVEL FOUR-CTL EPITOPE-JOINED PEPTIDE | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-20160235828-A1 | NOVEL PEPTIDE HAVING 4 LINKED CTL EPITOPES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20160017014-A1 | NOVEL PEPTIDE HAVING 5 LINKED CTL EPITOPES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2966092-A1 | NOVEL PEPTIDE HAVING 5 LINKED CTL EPITOPES | Taiho Pharmaceutical Co., Ltd. (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-20150202152-A1 | USE OF LIPOSOMES IN A CARRIER COMPRISING A CONTINUOUS HYDROPHOBIC PHASE AS A VEHICLE FOR CANCER TREATMENT | HORIZON TECHNOLOGY FINANCE CORPORATION | 2015-07-23 | — | — | US | disclosed |
| EP-1948225-B1 | USE OF LIPOSOMES IN A CARRIER COMPRISING A CONTINUOUS HYDROPHOBIC PHASE AS A VEHICLE FOR CANCER TREATMENT | IMMUNOVACCINE TECHNOLOGIES INC (CA) | 2013-12-11 | — | — | EP | disclosed |
| US-20090297593-A1 | Use of Liposomes in a Carrier Comprising a Continuous Hydrophobic Phase as a Vehicle for Cancer Treatment | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2009-12-03 | — | — | US | disclosed |
| EP-1948225-A4 | USE OF LIPOSOMES IN A CARRIER COMPRISING A CONTINUOUS HYDROPHOBIC PHASE AS A VEHICLE FOR CANCER TREATMENT | IMMUNOVACCINE TECHNOLOGIES INC (CA) | 2008-12-24 | — | — | EP | disclosed |
| EP-1948225-A1 | USE OF LIPOSOMES IN A CARRIER COMPRISING A CONTINUOUS HYDROPHOBIC PHASE AS A VEHICLE FOR CANCER TREATMENT | Immunovaccine Technologies Inc. (CA) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007041832-A1 | USE OF LIPOSOMES IN A CARRIER COMPRISING A CONTINUOUS HYDROPHOBIC PHASE AS A VEHICLE FOR CANCER TREATMENT | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137491-A1 | PEPTIDES AND USES THEREOF | CD274, TNFSF11, PDCD1LG2 | SLC7A5 3277/4885PTGS1 3403/4885ALPI 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.